Document is current

Article History

Received: 12 June 2020

Accepted: 4 October 2020

First Online: 12 October 2020

Ethics approval and consent to participate

: The present study was approved by the local Ethics Committee, “Comitato Etico di Area Vasta Centro, Regione Toscana”, Florence, Italy [rif. CEAVC 14334]. Given its observational design, the study did not involve any medical, pharmacological, or behavioral interventions in addition to the standard practice implemented by the physicians regardless of the registry. All research has been carried forth in agreement with the principles laid out in the original Declaration of Helsinki and its later amendments, and data were handled in agreement with patient informed consent.

: Not applicable

: The authors declare there is no competing interest related to the present manuscript and provide the following disclosures:Gianluca Villa has received support for travel expenses, hotel accommodations and registration to meetings from Baxter.Stefano Romagnoli has received honoraria for lectures/consultancy from Baxter, Orion Pharma, Vygon, intensive unit medical, MSD, and Medtronic and funds for travel expenses, hotel accommodation, and registration to meetings from Baxter, Pall International, Medigas, and Vygon.Silvia De Rosa has received speaker fees from BD-BARD and travel support from Sim Italia.Marco Resta has received speaker and consultancy fees from Baxter. Federico Prato has received speaker and consultancy fees from Baxter.Claudio Ronco has received support for acting as an advisory board member for ASAHI, Baxter, GE, Jafron, and Medtronic, and speaker fees from Astute, bioMérieux, B. Braun, Cytosorbents, ESTOR, FMC, and Toray, all unrelated to this manuscript.